Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | LDLR | P01130 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308797 | 0.83 | HTR7 (0.39) | KCNH2HTR1AHTR7HTR6MCHR1 | |
| SCHEMBL7121135 | 0.80 | NPC1 (0.32) | MCHR1 | |
| SCHEMBL5240858 | 0.78 | ALDH1A1 (0.40) | S1PR1RIPK2MCHR1CYP1A2 | |
| SCHEMBL7125272 | 0.77 | RIPK2 (0.41) | RIPK2HPGDSLDLRPCSK9 | |
| SCHEMBL306285 | 0.75 | MET (0.43) | — | |
| SCHEMBL306628 | 0.75 | MET (0.40) | RIPK2MCHR1LRRK2BDKRB2 | |
| SCHEMBL7675341 | 0.74 | PGR (0.34) | MCHR1 | |
| SCHEMBL10254634 | 0.74 | MCHR1 (0.34) | MCHR1 | |
| SCHEMBL7122716 | 0.74 | MCHR1 (0.33) | MCHR1 | |
| SCHEMBL7667702 | 0.74 | MCHR1 (0.31) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
| CN-1280580-A | Thienopyrimidine and thienopyridine derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-01-17 | — | — | CN | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | IDO1 1346/4885KCNH2 3889/4885S1PR1 344/4885 |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | IDO1 1159/4885KCNH2 2509/4885S1PR1 781/4885 |
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | IDO1 2450/4885KCNH2 3667/4885S1PR1 820/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | IDO1 4238/4885KCNH2 4750/4885S1PR1 453/4885 |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | IDO1 1121/4885KCNH2 2659/4885S1PR1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.